NEUROINFLAMMATION AND NEUROAXONAL INJURY IN PREDICTING ADVERSE DISEASE PROGRESSION IN PARKINSON’S DISEASE

Authors

  • Oxunova Diyoraxon Alisher kizi Author

Keywords:

Parkinson’s disease, neurofilament light chain, caspase-1, interleukin-6, MMP-9, neuroinflammation, prognosis, functional decompensation

Abstract

Parkinson’s disease (PD) shows variable progression, and clinical assessment alone may not fully predict future functional decline. This narrative review summarizes recent evidence on neurofilament light chain (NfL), caspase-1, interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9) as potential prognostic biomarkers. Current data suggest that NfL has the strongest association with neuroaxonal injury and adverse clinical outcomes, while caspase-1, IL-6, and MMP-9 may provide complementary information on neuroinflammation. Further prospective studies are required to confirm their independent and combined prognostic value.

References

[1] Kou W, Li S, Yan R, et al. Cerebrospinal fluid and blood neurofilament light chain in Parkinson’s disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis. J Neurol. 2025

272:311.

[2] Oizumi H, Hasegawa T, Kawahata I, et al. Associations among blood biomarkers, clinical subtypes, and prognosis in Parkinson’s disease. Clin Park Relat Disord. 2025

12:100313.

[3] Cabrera Ranaldi EDLRM, Nuytemans K, Martinez A, et al. Proof-of-Principle Study of Inflammasome Signaling Proteins as Diagnostic Biomarkers of the Inflammatory Response in Parkinson’s Disease. Pharmaceuticals (Basel). 2023

16(6):883.

[4] Kim R, Kim H-J, Shin JH, et al. Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson’s Disease. Mov Disord. 2022

37(7):1535–1541.

[5] Liu CZ, Guo DS, Ma JJ, et al. Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease. Front Aging Neurosci. 2022

14:889257.

[6] Senkevich K, Liu L, Alvarado CX, et al. Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis. npj Parkinsons Dis. 2024

10:145.

Published

2026-09-21